aTyr Pharma (ATYR) analyst forecast and price target
Analyst forecast
Consensus of 8 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Freedom Broker | Upgraded | Hold → Buy | $3.50 from $1.00 | May 20, 2026 |
| RBC Capital | Maintained | Sector Perform | $1.00 from $1.50 | Nov 7, 2025 |
| Wells Fargo | Downgraded | Overweight → Equal-Weight | $1.00 from $25.00 | Sep 16, 2025 |
| RBC Capital | Downgraded | Outperform → Sector Perform | $1.50 from $16.00 | Sep 16, 2025 |
| HC Wainwright & Co. | Downgraded | Buy → Neutral | — | Sep 15, 2025 |
| Jefferies | Maintained | Buy | $17.00 from $9.00 | Aug 22, 2025 |
| Wells Fargo | Maintained | Overweight | $25.00 from $17.00 | Jun 20, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $35.00 | Jun 4, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $35.00 | May 19, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $35.00 | Mar 14, 2025 |
| Leerink Partners | Initiated Coverage | Outperform | $16.00 | Feb 18, 2025 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Jan 6, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $35.00 | Dec 10, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $35.00 | Dec 3, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $35.00 | Oct 29, 2024 |
| Wells Fargo | Initiated Coverage | Overweight | $17.00 | Oct 4, 2024 |
| Jefferies | Initiated Coverage | Buy | $9.00 | Sep 5, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $35.00 | Aug 15, 2024 |
| RBC Capital | Maintained | Outperform | $16.00 | Aug 14, 2024 |
| HC Wainwright & Co. | Maintained | Buy | $35.00 | Aug 1, 2024 |
Frequently asked questions
Is ATYR a buy, sell, or hold?
Analysts covering aTyr Pharma currently average a Hold rating: 3 buy, 5 hold and 0 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on ATYR?
On May 20, 2026, Freedom Broker upgraded aTyr Pharma to Buy with a price target of $3.50.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.